Source:http://linkedlifedata.com/resource/pubmed/id/22069712
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2011-11-9
|
pubmed:abstractText |
The therapeutic potential of botulinum neurotoxin type A (BoNT/A) has recently been widely recognized. BoNT/A acts to silence synaptic transmission via specific proteolytic cleavage of an essential neuronal protein, SNAP25. The advantages of BoNT/A-mediated synaptic silencing include very long duration, high potency and localized action. However, there is a fear of possible side-effects of BoNT/A due to its diffusible nature which may lead to neuromuscular blockade away from the injection site. We recently developed a "protein-stapling" technology which allows re-assembly of BoNT/A from two separate fragments. This technology allowed, for the first time, safe production of this popular neuronal silencing agent. Here we evaluated the re-assembled toxin in several CNS assays and assessed its systemic effects in an animal model. Our results show that the re-assembled toxin is potent in inhibiting CNS function at 1 nM concentration but surprisingly does not exhibit systemic toxicity after intraperitoneal injection even at 200 ng/kg dose. This shows that the re-assembled toxin represents a uniquely safe tool for neuroscience research and future medical applications.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:status |
PubMed-not-MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
2072-6651
|
pubmed:author |
pubmed-author:CaleoMatteoM,
pubmed-author:DavletovBazbekB,
pubmed-author:FerrariEnricoE,
pubmed-author:HastingsMichael HMH,
pubmed-author:MaywoodElizabeth SES,
pubmed-author:NiranjanDhevahiD,
pubmed-author:PirazziniMarcoM,
pubmed-author:RestaniLauraL,
pubmed-author:RossettoOrnellaO,
pubmed-author:SchiavoGiampietroG
|
pubmed:issnType |
Electronic
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
345-55
|
pubmed:dateRevised |
2011-11-14
|
pubmed:year |
2011
|
pubmed:articleTitle |
Re-Assembled Botulinum Neurotoxin Inhibits CNS Functions without Systemic Toxicity.
|
pubmed:affiliation |
Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, UK; Email: eferrari@mrc-lmb.cam.ac.uk (E.F.); emaywood@mrc-lmb.cam.ac.uk (E.S.M.); mha@mrc-lmb.cam.ac.uk (M.H.H.); niranjan@mrc-lmb.cam.ac.uk (D.N.).
|
pubmed:publicationType |
Journal Article
|